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Abstract
Background: Macrophage migration inhibitory factor (MIF) is released into the intraluminal fluid
during bladder inflammation in the rat complexed to α1-inhibitor-3 (A1-I3; a rodent proteinase
inhibitor in the α-macroglobulin family). The location of A1-I3 in the bladder had not been
investigated. Therefore, we examined the location of A1-I3 and MIF/A1-I3 complexes in the bladder
and changes due to experimental inflammation.
Methods: Anesthetized male rats had bladders removed with no treatment (intact) or were
injected with Substance P (SP; s.c.; saline vehicle). After one hour intraluminal fluid was removed,
bladder was excised and MIF and A1-I3 levels were determined using ELISA and/or western-
blotting. MIF co-immunoprecipitation determined MIF/A1-I3 complexes in the bladder. Bladder
sections were immunostained for A1-I3 and MIF/A1-I3.
Results:  A1-I3 immunostaining was observed in interstitial spaces throughout the bladder
(including submucosa) but not urothelium in intact and saline-treated rats. RT-PCR showed that
the bladder does not synthesize A1-I3, therefore, A1-I3 in the interstitial space of the bladder must
be plasma derived. In SP-treated rats, A1-I3 in the bladder increased and A1-I3 was observed
traversing through the urothelium. Umbrella cells that do not show MIF and/or A1-I3
immunostaining in intact or saline-treated rats, showed co-localization of MIF and A1-I3 after SP-
treatment. Western blotting demonstrated that in the bladder MIF formed non-covalent
interactions and also binds covalently to A1-I3 to form high molecular weight MIF/A1-I3 complexes
(170, 130 and 75-kDa, respectively, verified by co-immunoprecipitation). SP-induced inflammation
selectively reduced 170-kDa MIF/A1-I3 in the bladder while increasing 170 and 130-kDa MIF/A1-I3
in the intraluminal fluid.
Conclusion: A1-I3 and MIF/A1-I3 complexes are resident in bladder interstitium. During SP-
induced inflammation, MIF/A1-I3 complexes are released from the bladder into the lumen. Binding
of MIF/A1-I3 complexes to urothelial cells during inflammation suggests these complexes
participate in the inflammatory reaction through activation of receptors for MIF and/or for A1-I3.
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Background
We have been studying the role of the pleiotropic and
pluripotent cytokine macrophage migration inhibitory
factor (MIF) in pelvic viscera inflammation. MIF, initially
recognized as released by T-cells to stop macrophage
migration, is expressed by different cells and involved in
various functions (e.g. cell proliferation, tumorigenesis
and inflammation) [1,2]. We first reported that MIF is
constitutively expressed in human and rat urothelium
[3,4]. Furthermore, cystitis (e.g. experimental in rats [5-7]
or bacterial in humans [8]) increased levels of MIF in the
intraluminal fluid (or urine) and upregulated MIF pro-
duction in the bladder. Because MIF stands upstream of
other inflammatory markers in the bladder [6], we
showed that sequestering intraluminal MIF with MIF
antisera decreased inflammatory bladder changes [9].
Thus, our experimental evidence supports the hypothesis
that MIF plays a central role in the development and/or
maintenance of bladder inflammation, in agreement with
MIF's importance in inflammatory conditions [1].
Our recent findings of high-molecular weight MIF-com-
plexes released into the intraluminal fluid of rats [10] and
human urine [8] were unexpected because in vitro studies
described a monomeric (12-kDa) and occasionally
dimeric (24-kDa) MIF conformation [11], while x-ray
crystallography revealed a trimeric (36-kDa) structure for
MIF [12]. However, we observed that intraluminal MIF
formed complexes by: (1) non-covalent associations (bro-
ken apart by lithium dodecyl sulfate and heat to yield 12-
kDa MIF) and (2) covalent associations (interrupted by
dithiolthreitol reducing agent [8,10]). Using mass spec-
troscopy, Western-blotting (WB) and co-immunoprecipi-
tation, we demonstrated covalently associated MIF with
α1-Inhibitor-3 (A1-I3) in the rat, while MIF was com-
plexed to ceruloplasmin, uromodulin, albumin and α2-
macroglobulin in human urine [8].
A1-I3 is a rodent monomeric proteinase inhibitor (appar-
ent molecular weight 180 kDa) in the α2-macroglobulin
family, with which it shares approximately 60% hom-
ology [13]. Both A1-I3 and α2-macroglobulin are synthe-
sized by the liver, released into the circulation due to
inflammation and taken up by inflamed organs [14]. A1-
I3 (and other members of α2-macroglobulin family of
protease inhibitors) bind to proteases at a bait region and
trap them in conformational changes that prevent further
action of the proteases. Once activated by protease bind-
ing to the bait-region, a receptor region is exposed that
allows clearing of the protease by binding to the low-den-
sity lipoprotein (LDL) receptor and also a cytokine bind-
ing site is exposed [15-17]. Several cytokines bind to
members of the α2-macroglobulin family (at sites other
than the bait-region) and may participate in distributing
those cytokines to specific targets [15].
We recently described MIF/A1-I3 complexes in the intra-
luminal fluid of the rat [10], however, the location of A1-
I3 in the bladder and whether MIF/A1-I3 complexes are
resident in the bladder or are the result of leakage of
plasma proteins during inflammation (plasma extravasa-
tion) had not been investigated. In the present study, we
examine the location of A1-I3 and MIF/A1-I3 complexes
in the bladder and describe changes induced by experi-
mental inflammation. In particular, we show that MIF/
A1-I3 complexes are resident in naïve bladders and during
Substance P-induced inflammation, there is translocation
of MIF/A1-I3 complexes to superficial urothelial cells only
along with release of MIF/A1-I3 complexes into the blad-
der lumen. This represents a novel finding and suggests
that MIF/A1-I3 complexes (and possibly other cytokines
associated with members of the α-macroglobulin family)
may participate in inflammatory processes in the bladder
through association with apical urothelial cells.
Methods
All experiments were approved by the institutional Ani-
mal Care Committee and conformed to the National
Institutes of Health guidelines for animal experimenta-
tion.
Substance P-induced bladder inflammation
SP-induced bladder inflammation was described in detail
previously [6,9,10,18]. Briefly, fifteen male rats (300–350
grams; Harlan; IN), anesthetized with sodium pentobar-
bital (60 mg/kg; i.p.) were divided into:
(1) Intact: Bladder was excised (N = 5)
(2) Saline: Bladder was isolated from the kidneys by tying
the ureters distally, cutting them centrally, and draining to
gauze pads. Urine was removed from the bladder and
replaced with saline (0.3 ml). Rats received saline (0.3 ml;
s.c.) and after 1 hour the intraluminal fluid (ILF) and
bladder were removed (N = 5);
(3) Substance P: Bladder was isolated as in (2) and urine
replaced with saline, but this group received substance P
(SP; 40 ug/kg; s.c.) and after 1 hour the ILF and bladder
were removed (N = 5).
Urine, ILF and bladders were processed for either immu-
nohistochemistry, protein and RNA as described [5-
7,9,10]. All animals were overdosed (sodium pentobarbi-
tal ;100 mg/kg; i.p.) at the end of the experiment.
Immunohistochemistry
Frozen bladder sections (10 microns) were exposed to A1-
I3 antisera (rabbit polyclonal; 1:1000; a gift from Dr.
Harry van Goor); and visualized using an ABC procedure
(Vector, Burlingame, California) and counterstained withBMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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hematoxylin. Double-immunofluorescence was per-
formed using antisera to MIF (Torrey Pines Biolabs, Hou-
ston, Texas; 1:200) and A1-I3 (1:1000). Primary antisera
were visualized using secondary antisera with FITC or
TRITC. Control experiments included omission of the pri-
mary antisera or omission of one of the two secondary
antisera (in the case of dual immunofluorescence).
Western-Blotting and MIF ELISA procedures
MIF Western-blotting (WB) was performed under native,
non-reducing and reducing conditions (Tris-glycine or
NuPAGE Bis-Tris gels, Invitrogen, Carlsbad, CA) as
described previously [10]. Briefly, total bladder homoge-
nates were prepared using 10 mM CHAPS buffer (3-[(3-
cholamidopropyl) dimethylammonio]-1-propane-sul-
fonate, 2 mM ethylenediaminetetraacetic acid and 4 mM
iodoacetate in phosphate buffered saline (PBS), pH 7.2
with the addition of general protease inhibitors (Sigma,
St. Louis, MO) and total protein concentrations in cleared
lysates determined so that equal protein concentrations
(10 μg) were loaded on all gels. For native conditions (i.e
non-reducing, non-denaturing), proteins were separated
on Tris-glycine gels using the reagents and as supplied by
the manufacturer (Invitrogen). Under non-reducing con-
ditions (i.e. non-reducing, denaturing), proteins were
heated to 70°C in the presence of lithium dodecyl sulfate
(LDS) prior to loading onto NuPAGE Bis-Tris gels (4–
12%, Invitrogen). Under reducing conditions (i.e. reduc-
ing, denaturing), proteins were heated to 100°C in the
presence of LDS and 50 mM dithiolthreitol prior to load-
ing onto NuPAGE Bis-Tris gels (4–12%, Invitrogen). In
addition, reducing conditions included addition of anti-
oxidant (Invitrogen) to running and transfer buffer to pre-
vent oxidation of reduced cysteine, methionine and tryp-
tophan residues. After electrophoresis, separated proteins
were transferred to PVDF. MIF protein bands were
detected using biotinylated polyclonal antibody (BAF289,
R&D Systems, Minneapolis, MN), strepavidin-HRP conju-
gates and chemiluminescent substrate (Pierce, Rockford,
IL). Blots were stripped (200 mM glycine pH 2.2, 1%
Tween-20, 0.1% SDS) then exposed to A1-I3 antisera
(1:1000) and detected as above. Recombinant rat MIF (15
ng; Torrey Pines) was run as a standard to estimate MIF
protein concentrations. Band intensities were quantified
using Kodak Image Station (Kodak, Rochester, NY).
MIF concentrations in bladder homogenates and ILF were
also determined using a rat MIF ELISA (Chemicon,
Temecula, CA). Data are expressed as mean ng/mg of pro-
tein (bladder) and ng/ml (ILF) ± S.E.M. from each treat-
ment group.
Co-Immunoprecipitation procedures
Bladder homogenates (250 μg protein) were used to iso-
late MIF interacting proteins by co-immunoprecipitation
using MIF antibody (5 μg; AB-289-PB, R&D Systems) and
protein G agarose beads following the manufacturer's pro-
tocol (Kirkegaard & Perry Laboratories, Gaithersburg,
MD) as described [18]. Briefly, bladder homogenate pro-
teins that non-specifically bind to protein G were
removed by a pre-clearing step in which the sample was
incubated with protein G beads for 1 h at 4°C. Following
the pre-clear step protein G agarose beads were discarded,
anti-MIF antibody added and samples incubated over-
night at 4°C with constant agitation. Freshly equilibrated
protein G beads were then added and the samples incu-
bated at 4°C for 2 h. The protein G beads were then exten-
sively wash and bound proteins eluted by the addition of
2 × NuPAGE LDS sample buffer and heating to 95°C for
15 min. The protein G eluted proteins were removed from
the beads by centrifugation, DTT added and the samples
heated to 100°C. The immunoprecipitated proteins were
separated by reducing NuPAGE Bis-Tris gels, transferred to
PVDF and A1-I3 immunostaining bands detected as
described for WB. Controls included incubation of pre-
cleared samples with non-specific IgG (Sigma) and sam-
ples processed without the addition of antibody in the
immunoprecipitation reaction.
PCR procedures
Bladder and liver total RNA was isolated using TriZol rea-
gent (Invitrogen) and reverse transcribed as described pre-
viously [7]. 2 μl aliquots of the resulting cDNA were
amplified for MIF and A1-I3 using low stringency condi-
tions: 35 cycles of 94°C 1 min, 50°C 1 min, 72°C 2 min.
MIF PCR primer design was described previously [5]; MIF
upstream primer: 5' CTCTCCGAGCTCACCCAGCAG 3',
downstream primer: 5' CGCGTTCATGTCGTAATAGTT 3'.
A1-I3 primers were designed to amplify 231 bp fragment
between nucleotides 3223–3453 of mRNA (upstream
primer: 5'CTCAAGTCTTTTGCCCAAGC3'; downstream
primer: 5'GGAGACAACGGGATCTGTGT3'). This region
spans exons 27–29 of the 58,910 bp A1-I3 gene located
on chromosome 4 (NW_047696, GeneBank). PCR gener-
ated fragments were separated and detected using 2% aga-
rose gels (E-Gel, Invitrogen). Controls for RT-PCR
reactions included: 1) separate amplification of GAPDH
(primers obtained from Ambion, Austin, TX) as a positive
control for total RNA concentrations and reverse tran-
scription reactions, 2) A1-I3 PCR amplification of liver
cDNA as a positive control for A1-I3 expression and 3)
total RNA without reverse transcriptase in PCR reaction as
a negative control.
Statistical Analyses
ELISA data were analyzed using t-tests. WB data were ana-
lyzed using t-tests (in the case of total intensity) or using
Two-way ANOVA (treatment × bands) followed by post-
hoc tests (Newman-Keuls) if significance was reached
(Prism4; GraphPad Software, San Diego, CA). Data areBMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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presented as mean ± SEM. Significance was defined as p <
0.05.
Results
SP-induced co-localization of MIF/A1-I3 in umbrella cells
A1-I3 immunostaining was demonstrated in the intact
bladder submucosa and interstitial space (Fig 1A;B). How-
ever, A1-I3 immunostaining was absent from the urothe-
lium. Similar findings were observed for saline treated
animals and Substance P treated animals (Figure 1C;1D).
Substance P treatment resulted in A1-I3 immunostaining
of the urothelium that previously showed no A1-I3. The
staining appeared to traverse the urothelium (Fig 1D and
insert), and surround urothelial cells (Fig. 1D and insert),
but did not appear to be cytoplasmic, in the basal and
intermediate layers of the urothelium. Superficial cells,
however, showed intense cytoplasmic A1-I3 immunos-
taining (Fig 1D; and insert).
RT-PCR analysis confirmed our previous results that doc-
umented MIF expression in the rat bladder and also dem-
onstrated MIF expression in the rat liver (Fig. 2). Under
low stringency RT-PCR conditions, no A1-I3 expression
was observed in the bladder (Fig. 2). Therefore since the
mRNA for this protein was not found in the bladder, it is
likely that A1-I3 is synthesized some place else (most
likely, liver) and then transported into the bladder and
stored in the tissues.
Using dual immunofluorescence, strong A1-I3 immunos-
taining was observed in the lamina propria, immediately
below the urothelium (Fig 3A) of saline treated rats, but
no A1-I3 was observed in the urothelium. Strong MIF
staining was observed in the urothelium while weak MIF
immunostaining was observed in the lamina propria (Fig
3B), in agreement with our previous reports [3]. In SP-
treated rats, A1-I3 immunostaining was now detected in
the urothelium, particularly umbrella cells that also
showed weak to moderate MIF immunostaining (Fig 3C–
H). Although A1-I3 immunostaining surrounding urothe-
lial cells was observed throughout parts of the urothe-
lium, the staining in the umbrella cells appeared
cytoplasmic. In addition, increased MIF immunostaining
was observed in the lamina propria (Fig 3C–H).
MIF and A1-I3 expression in the bladder and the liver Figure 2
MIF and A1-I3 expression in the bladder and the 
liver. MIF and A1-I3 mRNA were amplified by RT-PCR. 
Resulting PCR products were resolved on 2% agarose gels. A 
single MIF band was detected in both the bladder (B) and 
liver (L). A1-I3 message was detected only in the liver (L), but 
not in the bladder (B). GAPDH RT-PCR documented similar 
amounts of total RNA were extracted and amplified in both 
bladder (B) and liver (L).
Substance P-induced A1-I3 immunostaining in umbrella cells Figure 1
Substance P-induced A1-I3 immunostaining in 
umbrella cells. A1-I3 immunostaining in bladders from 
intact (A; B) and saline treated rats (C) showed A1-I3 in the 
interstitial spaces and in the lamina propria immediately 
below the urothelium, but not in the urothelium. In sub-
stance P-treated animals (D), however, A1-I3 immunostain-
ing was detected in the urothelium, particularly on umbrella 
cells. Note also immunostaining surrounding (but not intrac-
ellular) in the basal and intermediate layers of the urothelium 
(see insert) in SP-treated rats. Calibration bar: A = 400 um; 
B, C, D = 100 um; insert = 50 um.BMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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SP-induced changes in bladder MIF/A1-I3 complexes
In whole bladder homogenates, MIF WB under native
conditions revealed a broad band approximately 60–500
kDa (Fig 4A) indicating MIF formed large molecular
weight complexes in the bladder, similar to our earlier
observation in ILF [10]. Under non-reducing conditions,
4 prominent, distinct bands were observed corresponding
to apparent molecular weights of 170, 130, 75 and 12-
kDa (Fig. 4A). In addition, faint but distinct MIF bands
were also localized at 24-kDa and 15-kDa.
A1-I3 WB revealed a banding pattern that was similar to
that observed with MIF WB (Fig 4B) in that clear 75, 130
and 170-kDa bands were observed matching the MIF
bands. However, a 200-kDa band (not matching MIF) was
observed and there was a lack of a 12-kDa band (mono-
meric MIF), as expected. In fact, there were no bands
below 60-kDa.
Co-immunoprecipitation of whole bladder homogenates
using MIF antisera followed by A1-I3 WB, showed 4 dis-
tinct bands of 170, 130, 100 and 75-kDa (Fig 5). Thus, we
confirmed that 170,130 and 75-kDa bands are MIF/A1-I3
complexes. The appearance of an A1-I3 band at 100-kDa
likely represents protease activation of A1-I3 [19].
MIF complexes in serum, urine and intraluminal fluid
MIF non-reducing WB of serum, pre-treatment urine and
ILF (in saline and SP-treated rats) showed a similar pat-
tern to that reported by us previously [10], however, some
differences were observed. Briefly, serum showed only
170 and 130-kDa MIF bands, but no 12-kDa MIF (Fig 6),
while urine showed only 170 and 12-kDa MIF. The ILF, in
agreement with our previous report [10] showed all three
MIF bands. A MIF band at 75-kDa was not observed in any
of the fluids examined, indicating that this complex is
only present in the bladder. Previous mass-spectroscopy
analyses demonstrated that 170 and 130 bands corre-
spond to A1-I3 in the ILF [10], and A1-I3 WB showed cor-
responding bands in the present study for urine.
MIF protein amounts in bladder and ILF as determined by 
ELISA or Western-blotting
Both the ELISA and the WB findings showed decreased
MIF in the whole bladder homogenates after SP while the
amount in the ILF increased after SP (Table I; Fig 7A), in
agreement with our previous reports [6,9,10]. However,
the amounts reported by the ELISA were markedly less
than the amount estimated by WB. The discrepancy was
larger for the ILF, since the ELISA detected MIF protein lev-
els that were 3 orders of magnitude less than those esti-
mated by WB. There was no difference in the amount of
MIF detected by ELISA (Table I) in intact bladders when
compared to those treated with saline, indicating that our
experimental manipulations (e.g. injections to withdraw
urine and inject saline into the bladder), do not alter MIF
levels.
Using densitometry analysis of the intensities of the differ-
ent bands observed in WB we observed that in MIF WB, SP
treatment markedly decreased the 170-kDa band intensity
Colocalization of MIF/A1-I3 in umbrella cells after SP-treat- ment Figure 3
Colocalization of MIF/A1-I3 in umbrella cells after 
SP-treatment. Dual-immunofluorescence for A1-I3 and 
MIF in bladder sections from saline (A, B) and SP-treated rats 
(C–H). Bladders from saline-treated rats showed no A1-I3 in 
the urothelium (A; edge of unstained urothelium marked by 
long arrows) while the lamina propria (lp) showed significant 
A1-I3 immunostaining. On the other hand, MIF is present in 
the urothelium of saline-treated rats (B), mainly in basal and 
intermediate cells. Representative sections from three (3) 
different animals show that after substance P treatment, A1-
I3 immunostaining is seen in umbrella cells (C, E, G; arrows) 
that also co-localized MIF (D, F, H; arrows). In addition, 
increased staining in the lamina propria (lp) can be observed 
(D, F, H). Asterisk (H) shows area of superficial urothelium 
with MIF immunostaining but lacking A1-I3 immunostaining 
(G). Calibration bar = 100 um.BMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
Page 6 of 11
(page number not for citation purposes)
(Fig 7B) while changes in intensity in the other bands
(130, 75 and 12-kDa) did not reach statistical signifi-
cance. Similar analysis of the A1-I3 WB showed that SP
treatment increased the total amount of A1-I3 in the blad-
der (Fig 7C) through a preferential increase in the inten-
sity of the 170-kDA A1-I3 band while no statistically
significant changes were detected in the other bands (Fig
7D).
Discussion
In the present study, A1-I3 (a general protease inhibitor)
was found in the lamina propria and interstitial spaces of
intact bladders using immunohistochemistry. Since we
documented that the bladder does not synthesize A1-I3,
resident A1-I3 must be plasma derived, as has been also
reported for the kidney [14]. In addition, double-immun-
ofluorescence showed that, in intact and saline-treated
rats, basal and intermediate cells in the urothelium con-
tain only MIF (not A1-I3).
WB analysis under native conditions showed that there
was no uncomplexed MIF (e.g. trimeric at 36 kDa, or
monomeric at 12 kDa) in the bladder. Rather, MIF formed
high-molecular weight complexes that under non-reduc-
ing conditions resolved into 12-kDa (monomeric) MIF as
well as MIF/A1-I3 high-molecular weight bands indicat-
ing that MIF complexes are formed by noncovalent and
covalent interactions (MIF/A1-I3 resistant to non-reduc-
ing western-blotting conditions). Co-immunoprecipita-
tion with MIF antisera, followed by A1-I3 WB confirmed
MIF/A1-I3 complexes in the bladder. Our results show
that a considerable portion of the total MIF in the bladder
is associated with A1-I3, even in intact and saline treated
animals. Intact (not proteolytically activated) A1-I3 was
present in whole bladder homogenates as having an
apparent molecular weight of 200 kDa and did not have
MIF attached to it. Lower molecular weight MIF/A1-I3
complexes (170, 130, and 75 kDa) were observed after
non-reducing WB and likely reflect limited proteolysis of
A1-I3 as described [19]. Therefore, A1-I3 activated by pro-
teolytic activity is able to bind MIF in a process that occurs
even in the absence of inflammation (intact bladder).
High molecular weight MIF complexes (170 and 130-
kDa) and uncomplexed (12 kDa) MIF were also detected
in the ILF, and we previously documented that these were
MIF/A1-I3 complexes in bladder homogenates Figure 4
MIF/A1-I3 complexes in bladder homogenates. MIF WB under native, non-reducing and reducing conditions (A) showed 
that a broad band approximately 60–500 kDa under native conditions resolved into 4 distinct bands under non-reducing condi-
tions. These bands had the apparent molecular weight of 170, 130, 75 and 12 kDa. The 12-kDa band corresponds well with 
monomeric MIF. Under reducing conditions, only two high-molecular weight MIF bands with apparent molecular weights of 
130 and 75 kDa are present, in addition to the 12 kDa band. (B) A1-I3 WB under non-reducing conditions showed corre-
spondence to the high-molecular weight MIF bands (170, 130 and 75) indicating MIF/A1-I3 complexes. In addition, a 200-kDa 
A1-I3 band (marked by asterisk) was not detected under MIF WB, indicating that this form of A1-I3 is not bound to MIF. Sub-
stance P treatment appeared to decrease the 170-kDa MIF band, while increasing the intensity of the 200-kDa and 170-kDa 
A1-I3 bands. Under reducing conditions, an A1-I3 band at 100 kDa (marked by asterisk) can also be observed. For non-reduc-
ing and reducing WB, representative WB from two different animals in each group are presented. Apparent molecular weights 
(in kDa) are indicated by numbers to the right of the lanes.BMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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MIF/A1-I3 complexes [10]. While serum also contained
170 and 130 kDa MIF, pre-treatment urine contained only
170 kDa MIF complex. Thus, we consider it likely that the
130 kDa MIF complex (which is increased during SP treat-
ment) represents a fragment typically not released by the
bladder, except after inflammatory stimuli (or experimen-
tal manipulation such as puncturing the bladder to empty
Substance P-induced release of MIF/A1-I3 complexes in the  intraluminal fluid Figure 6
Substance P-induced release of MIF/A1-I3 complexes 
in the intraluminal fluid. A) MIF WB of serum, urine col-
lected before treatment and intraluminal fluid of saline 
treated vs SP-treated rats demonstrated differences in the 
forms of MIF found. Serum only contained high-molecular 
weight MIF complexes of 170 and 130-kDa apparent molecu-
lar weight. No 12-kDa MIF was detected in the serum. In 
pre-treatment urine, however, only 170-kDa MIF/A1-I3 (as 
verified by A1-I3 WB; data not shown) and 12-kDa MIF 
bands but no 130-kDa were observed. B) In the intraluminal 
fluid (ILF), 170 and 130-kDa bands, corresponding to MIF/A1-
I3 complexes [10] were noted along with 12-kDa MIF. SP 
treatment increased both 170 and 130 kDa MIF/A1-I3 
amounts in the ILF (Figure B).
Co-immunoprecipitation of MIF/A1-I3 from bladder homoge- nates Figure 5
Co-immunoprecipitation of MIF/A1-I3 from bladder 
homogenates. Co-immunoprecipitation of bladder 
homogenates followed by A1-I3 WB showed that MIF antis-
era was able to pull-down MIF/A1-I3 complexes with appar-
ent molecular weights of 170, 130, 100 and 80 kDa. H, L 
labels refer to heavy chain and light chain of IgG, respectively. 
A1-I3 WB was performed under reducing conditions.BMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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of urine and refill with saline). The 75-kDa MIF/A1-I3
complex that is only found in the bladder and not in any
of the fluids examined suggests that this fragment is an
organ-specific proteolytic fragment that does not exit the
bladder (presumably due to binding to membrane sur-
faces or intracellular location). Finally, 12-kDa MIF, while
found in bladder homogenates, urine and ILF, was not
detected in the serum by WB (non-reducing conditions)
likely due to the detection limits of WB when compared
to ELISA and/or the non-reducing conditions. Thus, simi-
lar to our recent findings in human serum [20], 12 kDa
MIF represents only a small portion of the total MIF found
in rat serum with MIF-protein complexes accounting for
the majority of the MIF in serum. Since bladder epithelia
in vitro [4] release 12-kDa MIF, we propose that MIF is
similarly released from basal and intermediate cells in the
rat urothelium (layers that show MIF immunostaining).
However, it quickly forms non-covalent and covalent
associations in the submucosa resulting in large-molecu-
lar weight complexes.
Treatment with SP increased MIF immunostaining in the
lamina propria (also staining for A1-I3), and interestingly,
MIF and A1-I3 co-localized in apical urothelial cells (cells
normally devoid of either MIF or A1-I3). A1-I3 immunos-
taining was observed surrounding (but not intracellular,
except for umbrella cells) urothelial cells after SP-treat-
ment suggesting that A1-I3 and MIF/A1-I3 travel between
basal and intermediate cells of the urothelium to reach the
apical surface and/or the intraluminal space. A similar
process of luminal entry of plasma proteins (particularly
α2-macroglobulin) has been described for airway epithe-
lia [21].
In agreement with our earlier findings, SP treatment
decreased the amount of MIF in the bladder, as detected
either by ELISA or WB (non-reducing conditions; Fig.
7A,B). However, a considerable discrepancy was noted
between the ELISA MIF amounts and those estimated by
WB (Table 1). We cannot fully account for this discrep-
ancy, however, we also recently reported that a well-
described ELISA to recognize human MIF in serum was
able to detect less than 1% of the total MIF detected by WB
[20]. Since the WB amounts in this study were estimated
from a single point, it is possible that the estimates are not
accurate when compared to the ELISA findings, although
still reflecting changes within the WB (eg. saline vs SP).
However, it is also likely that different antibodies (ELISA
vs WB) may differ in their ability to recognize and bind to
different forms of MIF (not just 12 kDa). Regardless of the
explanation for the discrepancy, and even though the
ELISA and WB findings agree in terms of the direction of
the findings (i.e. SP decreased MIF amounts in the blad-
der), ELISA findings lack valuable information concerning
changes in the different MIF complexes that are observed
using WB (non-reducing).
SP upregulates MIF expression in the bladder [6], there-
fore, we propose (Fig. 8) that MIF produced in the bladder
(most likely urothelial in origin) is released both into the
lumen and into the lamina propria where it binds to pro-
teolytically activated A1-I3 (resident in the interstitium,
but of liver origin). During inflammation, while the total
MIF content of the bladder decreases (a process that
argues against entry of serum-derived MIF playing a signif-
icant role), the different MIF/A1-I3 complexes change dif-
ferentially. SP-induced a decrease in resident 170-kDa
MIF/A1-I3 complexes (likely the result of proteolytic
Table 1: Comparison of ELISA and Western blotting in 
determining MIF levels
Chemicon ELISA Western Blotting
Bladder MIF (ng/mg protein)
Saline (n = 5) 694 ± 39.9 12870 ± 1150
Substance P (n = 5) 398 ± 56.7** 8765 ± 726.8*
ILF MIF (ng/ml)
Saline (n = 5) 2.5 ± 0.8 2821 ± 635.2
Substance P (n = 5) 19.0 ± 2.4*** 4338 ± 281.7*
* = p < 0.05; ** = p < 0.01; *** = p < 0.001
Effect of Substance P-treatment on specific MIF/A1-I3 com- plexes Figure 7
Effect of Substance P-treatment on specific MIF/A1-
I3 complexes. Substance P treatment decreased the total 
MIF detected in bladder homogenates (using WB under non-
reducing conditions) and this decrease was statistically signif-
icant (A). In addition, examining the changes in individual 
bands (under non-reducing conditions) showed that sub-
stance P treatment caused a significant decrease in the 170-
kDa band in bladder homogenates, while changes in other 
bands did not reach statistical significance (B). SP treatment 
also increased the total amount of A1-I3 in the bladder, pre-
sumably due to plasma extravasation (C). In particular, the 
170-kDa A1-I3 band was significantly increased (D). * = p < 
0.05; ** = p < 0.01.BMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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processing), while increasing the luminal levels of 130-
kDa MIF/A1-I3 and also 12-kDa MIF (non-covalently
complexed MIF). MIF and MIF/A1-I3 complexes travel
through the urothelium, enter the intraluminal space, and
some of them localize to umbrella cells, previously devoid
of MIF/A1-I3 (Fig. 8). Given that most of the MIF is found
complexed to A1-I3, A1-I3 may thus serve as a mechanism
to deliver MIF either to the intraluminal fluid or directly
to umbrella cells.
Plasma extravasation in the bladder has been described by
others [22], however, the process of MIF/A1-I3 travel
through the urothelium described in this study involves
exudation of protein complexes that are already resident
in the intact bladder. We did observe an increase in the
total amount of A1-I3 present in the bladder after SP treat-
ment consistent with plasma extravasation, as would be
expected. However, the total amount of MIF in the blad-
der (determined by ELISA and WB) decreased with SP
treatment, which argues against plasma extravasation con-
tributing to bladder MIF concentrations. Finally, the pres-
ence of specific MIF/A1-I3 complexes in the bladder only,
when compared to serum or urine, suggest that processing
of resident MIF/A1-I3 complexes (along with probable
formation of new complexes during inflammation)
account for the changes observed in this study.
The exact roles of the MIF/A1-I3 complexes or MIF non-
covalently bound to other carrier protein in bladder
inflammation remains to be determined. Our data in this
study, along with our recent findings with experimental
cystitis in rats [10] and bacterial cystitis in humans [8],
suggest that rather than studying total MIF concentrations,
particular attention needs to be paid to the associations of
MIF with other proteins in order to increase our under-
standing of the in vivo processing and function of this
cytokine. Transport of A1-I3 and/or MIF/A1-I3 complexes
through the urothelium is a likely mechanism for the
luminal entry of these complexes and their increase dur-
ing inflammation. Such complexes appear to differen-
tially bind to surface urothelial cells after SP-induced
inflammation, either as a result of travel across the urothe-
lium or from binding of soluble complexes in the intralu-
minal fluid. Our ELISA findings of decreased MIF in
whole bladder homogenates confirm our previous reports
[6,9,10] and suggest that while MIF and MIF/A1-I3 com-
plexes are being excreted during SP-induced inflamma-
tion, the relative amount of MIF and/or MIF/A1-I3
binding to apical cells in the urothelium is probably
small.
The receptor for MIF, CD74 has been recently identified
[23] and we described increased expression of the receptor
on urothelial cells after SP-induced inflammation [18].
Therefore, it is possible that MIF/A1-I3 binds to CD74
producing co-localization of MIF/A1-I3 in the apical
urothelium after SP-induced inflammation. Alternatively,
recent evidence showed that A1-I3 binds to cell-surface
glucose regulated protein 78 (GRP78) receptors in pros-
tate epithelia to activate signal transduction pathways
[24]. GRP78 is an endoplasmic reticulum stress protein
that is activated as part of the unfolded protein response
in mammalian cells to prevent apoptosis [25-27]. How-
ever, GRP78 can also be localized to the surface of cells
and be released into the circulation in inflammatory dis-
eases [28-30]. The location of GRP78 has not been inves-
tigated in the bladder, but it is possible that SP-induced
inflammation upregulates GRP78 in the urothelium thus
accounting for MIF/A1-I3 binding to umbrella cells previ-
ously devoid of A1-I3. This possibility is currently being
investigated and suggests that MIF and/or MIF/A1-I3
modulate inflammatory processes in the bladder through
interaction with two different receptor systems, CD74
(recognized receptor for MIF, presumably able to bind
MIF non-covalently bound to other carrier proteins) and/
or GRP78 (recognized receptor for A1-I3 and presumably
able to bind to MIF/A1-I3 complexes).
Model of MIF/A1-I3 complex formation and paracellular  transport through the urothelium Figure 8
Model of MIF/A1-I3 complex formation and paracel-
lular transport through the urothelium. In the intact 
bladder (A), A1-I3 (not synthesized by the bladder and most 
likely of liver origin) is located in the lamina propria immedi-
ately below the urothelium and throughout the interstitial 
spaces in the bladder. MIF is found in the urothelium, in the 
basal and intermediate cells. The lamina propia shows only 
weak MIF immunostaining. There is basal MIF release (and 
MIF/A1-I3 complexes) into the bladder lumen, however, A1-
I3 is not located in the urothelium of intact rats. After SP-
induced neurogenic inflammation (B), there is upregulation of 
MIF production in the urothelium, increased MIF staining in 
the lamina propria and greater release of MIF and MIF/A1-I3 
complexes. Paracellular transport of A1-I3 can be observed 
in the urothelium. In addition, apical (umbrella cells) are now 
observed co-localizing both MIF and A1-I3.BMC Urology 2006, 6:24 http://www.biomedcentral.com/1471-2490/6/24
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Regardless of the relative contribution of either receptor
system to MIF-mediated bladder inflammation, seques-
tering intraluminal MIF with anti-MIF antibodies was able
to reduce and/or reverse SP-induced inflammatory
changes in the bladder [9]. However, determination of the
contribution of either MIF acting through (presumably)
CD74 receptors or MIF/A1-I3 complexes acting through
(presumably) GRP78 receptors will help specify targets to
reduce MIF-mediated inflammation. Recent evidence
examining MIF complexes in human urine from UTI
patients (e.g. MIF-ceruplasmin; MIF/α2-macroglobulin)
suggest that interaction with other proteins may contrib-
ute to MIF's effect on this organ and may prove a general
mechanism for MIF-mediated inflammation.
Conclusion
A1-I3 (a general protease inhibitor of liver origin) and
MIF/A1-I3 are resident in the interstitium, but not urothe-
lium, in intact bladders. SP increased MIF immunostain-
ing in the lamina propria, along with an increase in MIF/
A1-I3 release into the intraluminal fluid, and co-localiza-
tion of MIF/A1-I3 in umbrella cells previously devoid of
either. Thus, A1-I3 may serve as carrier/delivery protein
for MIF that is synthesized by urothelial cells.
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